Shenzhen Kangernuo Biotechnology Co., Ltd. relies on the Institute of Microbiology of the Chinese Academy of Sciences as a research and development platform, with the corporate purpose of extending human life and improving national health, and is committed to applying biotechnology to treat major diseases such as cancer and hepatitis B. The research and development of drugs and treatment methods promotes the market transformation of scientific and technological achievements and contributes to improving human health.
The Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, is the only research group at home and abroad that systematically studies the use of heat shock proteins to develop vaccines for hepatitis B virus infectious diseases and cancer. The relevant patent applied for "Complex of Hepatitis B Virus Antigen Polypeptide and Heat Shock Protein and Its Application" has been authorized by China (ZL 01 1 04060.2, 2003), and an international patent application has been submitted, and it has been authorized by the United States patent (PCT/CN01/ 00295, US 7247 712 B2, Jul. 24, 2007). The project has received support from the National 973 Project, 863 Project, major projects of the Chinese Academy of Sciences, Natural Science Foundation projects, and cutting-edge projects of the Institute of Microbiology. It has published more than 20 related SCI papers with an impact factor of more than 100. Relevant research results have been reported by Natue (429(17):715,2004), Nature Reviews Cancer (4:500-501,2004), PNAS (103(46):17073-17074,2006), etc.
Shenzhen Kangernuo Biotechnology Co., Ltd. has been authorized by the Institute of Microbiology, Chinese Academy of Sciences, and has the patent "Complex of Hepatitis B Virus Antigen Polypeptide and Heat Shock Protein and its Application" (Tian Bo, Meng Songdong, Gao Fu, ZL 01 1 04060.2, 2003; PCT/CN01/00295, US 7247 712 B2, Jul. 24, 2007). The company cooperates with the Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, to jointly develop therapeutic vaccine products and preparation technologies for the treatment of major diseases such as cancer and hepatitis B. Currently, the Ruiberson autologous tumor vaccine we have developed has been It has been clinically applied in the Cancer Hospital of the Chinese Academy of Medical Sciences and achieved good results.
Currently, we are the first in China to apply the Robuson autologous tumor vaccine for clinical treatment of patients with malignant tumors such as liver cancer, breast cancer, and digestive tract cancer. Clinical studies have shown that Robson's autologous tumor vaccine can effectively delay tumor recurrence, prolong patient survival and improve patients' quality of life.